These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36808638)

  • 1. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants.
    Liu J; Solan R; Wolk R; Plotka A; O'Gorman MT; Winton JA; Kaplan J; Purohit VS
    Br J Clin Pharmacol; 2023 Jul; 89(7):2208-2215. PubMed ID: 36808638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
    Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
    Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
    Thai C; Tayo B; Critchley D
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.
    Chen X; Isambert N; López-López R; Giovannini M; Pognan N; Kapoor S; Quinlan M; You B; Cui X; Rahmanzadeh G; Mau-Sorensen M
    Br J Clin Pharmacol; 2023 Mar; 89(3):1046-1055. PubMed ID: 36131603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
    Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
    Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
    Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
    J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
    Backman JT; Granfors MT; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants.
    Cox DS; Rehman M; Khan T; Ginman K; Salageanu J; LaBadie RR; Wan K; Damle B
    Br J Clin Pharmacol; 2023 Nov; 89(11):3352-3363. PubMed ID: 37354048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.
    Zhou D; Sunzel M; Ribadeneira MD; Smith MA; Desai D; Lin J; Grimm SW
    Br J Clin Pharmacol; 2012 Jul; 74(1):98-108. PubMed ID: 22122233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics.
    Purohit V; Huh Y; Wojciechowski J; Plotka A; Salts S; Antinew J; Dimitrova A; Nicholas T
    AAPS J; 2023 Mar; 25(3):32. PubMed ID: 36977960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.